Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
228 hedge funds and large institutions have $2.79B invested in Global Blood Therapeutics, Inc. in 2020 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 85 increasing their positions, 62 reducing their positions, and 55 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 62
2% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 55
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
0% less funds holding
Funds holding: 229 → 228 (-1)
20% less capital invested
Capital invested by funds: $3.51B → $2.79B (-$718M)
24% less call options, than puts
Call options by funds: $43.1M | Put options by funds: $57M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$64.7M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$39.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$31.3M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$26.7M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$23.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$111M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$46.9M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$33.1M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$29.5M |
| 5 |
Millennium Management
New York
|
-$27.2M |
GBT Hedge Fund Activity: Q4 2020 in Review
228 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q4 2020, worth a combined $2.79B — down 20% from $3.51B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new GBT positions and 55 closed out — a net gain of 1 holder — while 85 added to existing stakes and 62 trimmed.
The largest buyer was Pictet Asset Management (UK), adding an estimated $64.7M. The largest seller was Fidelity Investments, cutting an estimated $111M.
- 228 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q4 2020, down from 229 in Q3 2020.
- Funds reported $2.79B of Global Blood Therapeutics, Inc. stock for Q4 2020, down 20% quarter-over-quarter.
- 56 funds opened new Global Blood Therapeutics, Inc. positions in Q4 2020 and 55 closed out, a net change of +1 holder.
- The largest Global Blood Therapeutics, Inc. buyer in Q4 2020 was Pictet Asset Management (UK), an estimated $64.7M added.
- The largest Global Blood Therapeutics, Inc. seller in Q4 2020 was Fidelity Investments, an estimated $111M sold.
Based on aggregated 13F filings for Q4 2020.